Cambrex Signs Agreement To Acquire ProSyntest AS

Download image

A F CAMBREX LOGO CAMBREX LOGO Cambrex Corporation logo. (PRNewsFoto) (Newscom TagID: prnphotos042906)[KS] EAST RUTHERFORD, NJ UNITED STATES 01/05/2005

    EAST RUTHERFORD, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Cambrex
 Karlskoga AB, a subsidiary of Cambrex Corporation (NYSE:   CBM), is pleased
 to announce it has entered into a purchase agreement for all of the stock
 of ProSyntest AS, a privately held active pharmaceutical ingredients
 ("API") research and development company. ProSyntest employs approximately
 twenty five chemists located within the Tallinn Technology Park in Tallinn,
 Estonia. ProSyntest, formed in 1990 as a spin off from Tallinn University
 of Technology, has strengths in cost effective chemical route selection and
 sample generation, rapid scale up of products at kilo lab scale, as well as
 chiral and organometallic chemistries.
 
     (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
 
     "Cambrex Karlskoga has successfully worked with the ProSyntest chemists
 for the past fifteen years, and the acquisition of the business is a
 natural extension of our long standing relationship. ProSyntest, located in
 Eastern Europe, will enable Cambrex to more effectively compete in the high
 growth early clinical stage pharmaceutical custom development market and
 provide us with a strong pool of talented chemists to advance numerous
 proprietary strategic initiatives," commented Steven Klosk, Executive Vice
 President & COO of Cambrex Corporation.
 
     The business will be renamed Cambrex Tallinn after completion of the
 acquisition. Cambrex intends to add more process and analytical chemists at
 the site and continue early API development work in Tallinn for scale up at
 Karlskoga and the other Cambrex manufacturing facilities.
 
     About Cambrex
 
     Cambrex provides products and services to accelerate the development
 and commercialization of small molecule active pharmaceutical ingredients
 ("APIs"), advanced intermediates and other products for branded and generic
 pharmaceuticals. The Company currently employs approximately 850 people
 worldwide. For more information, please visit http://www.cambrex.com.
 
 
 

SOURCE Cambrex Corporation